Delivery Order SPE2DP16D0008-0004
Award Date
9/20/16
Potential Completion Date
9/20/17
Potential Value
$259K
Federal Agency
Medical Supply Chain
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract has a firm fixed price, with a ceiling value of $88,842.60, and was awarded on September 8, 2017 with a completion date of September 10, 2018. The contract was not set aside for any special designation. Genentech holds several key contract vehicles with...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $85,938.87. The contract has a firm fixed price and does not utilize any set-aside designations. Genentech has several existing contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule...
This is a delivery order (SPE2DP16D0008|0041) awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $9,862,682.40 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication, to support the federal government's medical supply needs. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal...
This is a delivery order under a Federal Supply Schedule contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $8,434,278.00 and a period of performance ending on September 20, 2017. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal agencies,...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company. The $93,573.18 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication. The award falls under a larger indefinite delivery contract between Genentech and DLA valued at $27.9 million to supply medical supplies and critical pharmaceuticals for the Department of Defense. No set-aside designation was used....
This is a federal contract award to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, by the Defense Logistics Agency (DLA) for the delivery of oseltamivir phosphate, an antiviral medication. The contract award (SPE2DP18D0011|SPE2DP18F6027) has a ceiling value of $95,976.93 and was issued on a firm fixed-price basis as a delivery order, with a final completion date of September 23, 2019. Genentech is an established federal contractor, holding several vehicles with...
This is a firm fixed-price delivery order contract awarded by the Medical Supply Chain, a component of the Department of Defense, to Genentech USA, Inc. The contract has a ceiling value of $353,101.26 and is for the delivery of oseltamivir phosphate, an antiviral medication. The contract was awarded under a larger federal supply schedule contract between Genentech and the Department of Veterans Affairs, valued at $4.9 billion, that enables the company to efficiently provide pharmaceuticals and...
This is a Delivery Order (SPE2DP19F5699) awarded by the Medical Supply Chain, a component of the Defense Logistics Agency (DLA), to Genentech USA, Inc. for the supply of oseltamivir phosphate, an antiviral medication, at a Firm Fixed Price of $95,996.16. The contract has an ultimate completion date of September 3, 2020. Genentech is a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics that holds several contract vehicles with federal agencies, including a $4.9 billion...
This federal contract award, SPE2DP18D0011|SPE2DP18F6016, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The contract, valued at $115,959.93, is for the delivery of oseltamivir phosphate, a critical antiviral medication. The contract is a firm fixed-price Delivery Order, with a completion date of August 3, 2023. Genentech USA, Inc. has previously received several significant federal contract...
The Defense Logistics Agency Troop Support Medical awarded a firm-fixed-price delivery order to Genentech USA, Inc., a biotechnology company that manufactures pharmaceutical products, for the supply of the antiviral medication Oseltamivir Phosphate. The $179,992.80 contract has a completion date of September 23, 2019 and does not utilize any set-asides. Genentech, as the prime contractor, will perform the work at its facility in South San Francisco, California. This delivery order is part of...